SBIR/STTR Research Award

Bone Targeting of Degradable Drug-Filled Nanoparticles

Award identifier 58394ea8fd921fe31c2599625c762e54d48efc27491359ab13c7049037c28efcAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$221,401

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
COMCHEM TECHNOLOGIES, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): A major limitation to using small injectable particles containing therapeutic drugs for controlled drug delivery is their quick removal from the bloodstream by mononuclear phagocytes mainly in the liver and spleen. Recent advances in how to make biodegradable nanoparticles invisible to such processes (stealth nanoparticles) using polyethylene glycol coatings have allowed for much longer circulation times which we hypothesize make possible new targeting strategies. We propose to target such stealthy drug-laden biodegradable nanoparticles to the hydroxyapatite surface of bone using covalent attachment of certain chelating groups to the surface of the nanoparticte. The drug we propose incorporating into the nanoparticle is known to protect cells from the harmful effects of chemotherapy and radiation therapy. If successful, our targeting technology could allow for selective delivery of protectant drug-containing nanoparticles to the bone whereupon biodegradation would liberate free active drug causing selectively high concentrations in the nearby contiguous bone marrow. Such selective protectant delivery to marrow could allow for more aggressive treatments of some cancers without the need for bone marrow transplants. The targeting technology proposed is a platform technology as it is amenable to substituting in other therapeutic drugs in the novel nanoparticles such as chemosensitizers or chemotherapy agents.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.